Bold claim upfront: Psychosis is not a single, simple story—it unfolds through a tangled mix of brain development, symptoms, cognition, and how we treat it. But here’s where it gets controversial: the brain’s structure and how we respond to treatment can shape the course of the illness in surprising ways. This article explains what researchers found and why a personalized approach matters for understanding and managing psychosis.
Psychosis refers to a cluster of symptoms—like hallucinations and delusions—that disrupt contact with reality. These symptoms can appear at the first psychotic episode and then evolve differently from person to person, making schizophrenia a particularly intricate condition to study and treat.
In this study, scientists looked at the cerebral cortex in people experiencing psychosis and found that brain changes are not uniform. At the first episode, patients tended to have reduced cortical volume, especially in areas rich in serotonin and dopamine receptors. These neurotransmitters are central to both how psychosis develops and how antipsychotic medications work. The findings also point to other brain cells involved in inflammatory and immune processes playing a potential role.
Treatment appears to slow the pace of these structural changes over time, suggesting clinical intervention can protect the brain to some extent. Yet, individuals who require higher doses of antipsychotics over time tend to show more persistent differences, which may reflect more severe symptoms rather than a direct effect of the medication on brain volume.
Cognition is affected early on as well. Many participants exhibited cognitive impairments from the outset, and while some improvement occurred as symptoms stabilized, this recovery tended to be less pronounced in those needing higher-dose treatments.
The research, led by Claudio Alemán Morillo and Rafael Romero García at the Neuroimaging and Brain Networks Laboratory of the University of Seville, analyzed MRI scans from 357 people with schizophrenia and 195 control participants. The team tracked changes over a decade, linking brain region volumes to clinical symptoms and cognitive performance, including attention, memory, and processing speed.
A notable methodological advance was the use of percentile-based analysis for brain volumes for the first time in this context. Similar to how pediatric growth percentiles identify deviations in height or weight, percentiles help identify atypical brain volumes across regions.
In short, psychosis involves dynamic brain changes that vary across individuals. Early brain imaging and careful clinical management can influence long-term outcomes, but the relationship between dose, symptoms, and brain structure is complex and warrants personalized treatment plans.
Would you like this rewritten version adjusted for a specific audience (patients, caregivers, clinicians), or expanded with short practical takeaways and questions to spark discussion in the comments?
